Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: A systematic review and meta-analysis

Clinical Infectious Diseases

Volumn 61, Issue 9, 2015, Pages 1453-1461

  Boender, T Sonia ^a   Sigaloff, Kim C E ^a   Mcmahon, James H ^b,c   Kiertiburanakul, Sasisopin ^d   Jordan, Michael R ^c   Barcarolo, Jhoney ^e   Ford, Nathan ^e   Rinke De Wit, Tobias F ^a   Bertagnolio, Silvia ^e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ALFRED HOSPITAL   (Australia)

^c TUFTS MEDICAL CENTER   (United States)

^d MAHIDOL UNIVERSITY   (Thailand)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

antiretroviral therapy; HIV 1; low and middle income countries; virological monitoring

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT;

FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTENTION TO TREAT ANALYSIS; LOWEST INCOME GROUP; META ANALYSIS; PRIORITY JOURNAL; PUBLICATION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADOLESCENT; ADULT; AGED; DEVELOPING COUNTRY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PROCEDURES; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84946731866     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ556     Document Type: Review

References (23)

1. World Health Organization. Global update on the health sector response to HIV, 2014, 2014. Available at: http://www.who.int/hiv/pub/progressreports/update2014/en/. Accessed 2 April 2015.
2. World Health Organization. Access to antiretroviral drugs in lowand middle-income countries: technical report July 2014. Geneva, Switzerland, 2014. Available at: http://www.who.int/hiv/pub/amds/access-Arv-2014/en/. Accessed 2 April 2015.
3. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-10.
4. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection-Recommendations for a public health approach. Geneva, Switzerland, 2013. Available at: http://www.who.int/hiv/pub/guidelines/arv2013/down load/en/. Accessed 5 July 2013.
5. Keebler D, Revill P, Braithwaite S, et al. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. Lancet Glob Heal 2014; 2:e35-43.
6. UNAIDS (Joint United Nations Programme on HIV/AIDS). Ambitious treatment targets: writing the final chapter of the AIDS epidemic: writing the final chapter of the AIDS epidemic. Geneva, 2014.
7. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-Analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6:e1000100.
8. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 82:251-9.
9. Hamers RL, Oyomopito R, Kityo C, et al. Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance-HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol 2012; 41:43-54.
10. World Bank. World Bank list of economies. Available at: http://data. worldbank.org/about/country-classifications/country-And-lendinggroups. Accessed 10 May 2013.
11. World Health Organization. HIV drug resistance early warning indicators-June 2010 update. Geneva, Switzerland, 2010. Accessed 20 March 2013.
12. UNAIDS (Joint United Nations Programme on HIV/AIDS). 90-90-90-An ambitious treatment target to help end the AIDS epidemic, 2014. Available at: http://www.unaids.org/en/resources/documents/2014/90-90-90. Accessed 20 March 2015.
13. Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol 2008; 8:79.
14. StataCorp. 2009. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP.
15. van Sighem A, Gras L, Kesselring A, et al. SHM Monitoring Report 2013-HIV Infection in the Netherlands. November 2. Amsterdam: Stichting HIV Monitoring, 2013. Available at: http://www.hiv-moni toring.nl/nederlands/onderzoek/monitoring-reports/. Accessed 25 March 2014.
16. Nosyk B, Montaner JS, Colley G, et al. The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study. Lancet Infect Dis 2014; 14:40-9.
17. Gupta RK, Goodall RL, Ranopa M, et al. High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy. Clin Infect Dis 2014; 58:1023-6.
18. Okello V, Dlamini S, Jobanputra K, Parker LA, Papo J, Azih C. Routine viral load (VL) monitoring for targeted adherence support among antiretroviral therapy (ART) patients in a resource-limited setting, Swaziland. In: 8th International Conference on HIV Treatment and Prevention. 2013.
19. Barth RE, van der Loeff MFS, Schuurman R, Hoepelman AIM, Wensing AMJ. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10:155-66.
20. McMahon JH, Elliott JH, Bertagnolio S, Jordan MR. Viral suppression after 12 months of antiretroviral therapy in low-And middle-income countries: a systematic review. BullWorldHealthOrgan 2013; 91:377-85.
21. Hammond R, Harry TC. Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures-A metaanalysis. Int J STD AIDS 2008; 19:291-6.
22. López-Martínez A, O'Brien NM, Caro-Vega Y, Crabtree-Ramírez B, Sierra-Madero J. Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico. J Acquir Immune Defic Syndr 2012; 59:155-60.
23. McMahon JH, Medland N. 90-90-90: How Do We Get There? Lancet HIV 2014; 1:e10-1.